-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
【Star Enterprise of Chemical Machinery and Equipment Network ] In recent years, with the support of national policies and the booming trend of the biopharmaceutical market, the domestic innovative medicine industry has begun to accelerate its development.
At present, regardless of multinational pharmaceutical giants, domestic pharmaceuticals, or small and medium-sized innovative R&D companies, they are all arranging and fighting in the Chinese innovative drug market.
However, it is worth noting that many innovative drug companies have begun to choose to build their own factories while deploying their products for commercial production.
Star Enterprise of Chemical Machinery Equipment NetworkChemical machinery and equipmentAt present, regardless of multinational pharmaceutical giants, domestic pharmaceuticals, or small and medium-sized innovative R&D companies, they are all arranging and fighting in the Chinese innovative drug market.
However, it is worth noting that many innovative drug companies have begun to choose to build their own factories while deploying their products for commercial production.
For example, on May 16, 2019, Tianjing Biotech signed a cooperation agreement with Hangzhou Qiantang New District.
The company plans to invest about 5.
6 billion yuan to establish an antibody research and development and industrialization base, which indicates that it has been relying on the CDMO outsourcing model for projects.
The promoted Tianjing Biology will build its own factory for production in the commercialization stage.
The company plans to invest about 5.
6 billion yuan to establish an antibody research and development and industrialization base, which indicates that it has been relying on the CDMO outsourcing model for projects.
The promoted Tianjing Biology will build its own factory for production in the commercialization stage.
On September 27, 2019, BeiGene announced the official completion of the first phase of its Guangzhou biopharmaceutical production base.
In the same year, Fuhong Henlius started to build the Songjiang Biopharmaceutical production base on the basis of the existing Xuhui production base.
Junshi Biology also opened the Shanghai Lingang production base outside the original Suzhou Wujiang pilot clinical drug and commercial production base.
In addition, Zai Lab also established a commercial small molecule production base and a large molecule pilot production base in Suzhou in 2017 and 2018.
In the same year, Fuhong Henlius started to build the Songjiang Biopharmaceutical production base on the basis of the existing Xuhui production base.
Junshi Biology also opened the Shanghai Lingang production base outside the original Suzhou Wujiang pilot clinical drug and commercial production base.
In addition, Zai Lab also established a commercial small molecule production base and a large molecule pilot production base in Suzhou in 2017 and 2018.
In recent years, pharmaceutical companies, especially innovative R&D companies, have built their own factories.
The industry believes that this is mainly due to the fact that the domestic pharmaceutical industry has entered the commercialization stage.
In the past, many innovative pharmaceutical companies would choose CDMO foundry in the R&D stage to save costs and speed up R&D time.
However, when the innovative results began to appear, in order to reach patients on a large scale, pharmaceutical companies still chose to build their own factories.
.
The industry believes that this is mainly due to the fact that the domestic pharmaceutical industry has entered the commercialization stage.
In the past, many innovative pharmaceutical companies would choose CDMO foundry in the R&D stage to save costs and speed up R&D time.
However, when the innovative results began to appear, in order to reach patients on a large scale, pharmaceutical companies still chose to build their own factories.
.
It is worth noting that with the arrival of the wave of pharmaceutical companies building factories, the industry believes that my country's pharmaceutical industry may enter the accelerated stage of innovation and development, and the demand for pharmaceutical R&D and production will also continue to increase.
In this case, our countryThe pharmaceutical equipment industry will also usher in huge opportunities and challenges.
Pharmaceutical equipmentIn this case, our countryThe pharmaceutical equipment industry will also usher in huge opportunities and challenges.
After all, domestic pharmaceutical equipment companies have always met customer needs as a prerequisite for product design and research and development.
As pharmaceutical companies enter the innovation period and build their own factories in order to meet the production needs and speed of new drugs, they will naturally put forward higher requirements on R&D and production processes.
In this case, pharmaceutical equipment companies must continue to innovate and upgrade technology and process equipment to meet customer needs.
It is understood that in order to meet the needs of smart factories of pharmaceutical companies, some powerful domestic pharmaceutical machine companies have embarked on the road of increasing R&D investment and committed to improving product automation and intelligence.
As pharmaceutical companies enter the innovation period and build their own factories in order to meet the production needs and speed of new drugs, they will naturally put forward higher requirements on R&D and production processes.
In this case, pharmaceutical equipment companies must continue to innovate and upgrade technology and process equipment to meet customer needs.
It is understood that in order to meet the needs of smart factories of pharmaceutical companies, some powerful domestic pharmaceutical machine companies have embarked on the road of increasing R&D investment and committed to improving product automation and intelligence.
For example, Chutian successfully launched the application of smart pharmaceutical engineering overall solutions in China, including vials, ampoules, oral liquid bottles, cartridge bottles, prefilled needles, three-in-one blow-filling, soft bags and large The fully automated production equipment and information management system for the production of a series of sterile medicines such as infusion glass bottles have created a digital and intelligent manufacturing factory through the deep integration of information technology and manufacturing technology.
In fact, with the strong support of national policies and the vigorous advancement of related pharmaceutical equipment companies, my country's smart pharmaceutical equipment industry has made great breakthroughs in recent years.
However, it should be noted that, from the current point of view, the overall level of intelligence of my country's intelligent intelligent pharmaceutical equipment, compared with advanced technology, there is still a certain gap.
However, it should be noted that, from the current point of view, the overall level of intelligence of my country's intelligent intelligent pharmaceutical equipment, compared with advanced technology, there is still a certain gap.
Therefore, for the development of intelligent pharmaceutical equipment, some experts suggest that, in addition to improving equipment quality, automation, digitization, networking, and intelligence, Chinese pharmaceutical equipment companies also need to explore the application of some new supporting technologies and devices based on actual conditions.
Such as PAT technology, robots, 3D printing technology, etc.
, to further improve the true "intelligence" of smart pharmaceutical equipment.
Such as PAT technology, robots, 3D printing technology, etc.
, to further improve the true "intelligence" of smart pharmaceutical equipment.
In general, in order to speed up the launch and production of new drugs, many domestic innovative pharmaceutical companies that have achieved independent commercial production will choose to use more intelligent and efficient pharmaceutical equipment or production lines.
In the face of such good opportunities, domestic pharmaceutical companies need to base themselves on their own development positioning, by creating scientific strategies, constantly using innovative methods to enhance product competitiveness, and to find a path that conforms to market trends and meets customer needs, so as to Win more market share in the future.
In the face of such good opportunities, domestic pharmaceutical companies need to base themselves on their own development positioning, by creating scientific strategies, constantly using innovative methods to enhance product competitiveness, and to find a path that conforms to market trends and meets customer needs, so as to Win more market share in the future.
Original title: Innovative pharmaceutical companies have built their own factories, and the opportunity for pharmaceutical machinery companies is here
